Clinical trials: Dietary Hyperoxaluria
Healthy, Enteric Hyperoxaluria
Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
This Phase 1, first-in-human, randomized, double-blinded, placebo controlled study is evaluating FB-001 in healthy volunteers (Part 1) and participants diagnosed with enteric hyperoxaluria (Part 2).
- Trial name
- NCT05650112
- Testing
- FB-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federation Bio Inc.
Enteric Hyperoxaluria
Gut Kidney Axis in Enteric Hyperoxaluria
40 subjects with a confirmed diagnosis of IBD or >6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3…
- Trial name
- NCT05124886
- Testing
- Moderately High Oxalate (MOx) Diet
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Enteric Hyperoxaluria, Hyperoxaluria
Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
The purpose of this study is to learn more about a condition called 'unclassified hyperoxaluria'. People with this condition have large amounts of oxalate in their urine, which can cause kidney stones and kidney failure.
- Trial name
- NCT00588120
- Testing
- C-13 labeled oxalate
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Secondary Hyperoxaluria, Nephrolithiasis
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Identify individuals with greater absorption of oxalate based on increase in urinary oxalate excretion in response to a controlled oxalate-rich test meal.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT03095885
- Testing
- Test Meal
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Allena Pharmaceuticals
Nephrolithiasis
Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria
Oxalate restricted diet is routinely prescribed in clinical practice of nephrolithiasis patients with hyperoxaluria. The effect of dietary oxalate on urinary oxalate is however controversial.
- Trial name
- NCT01650935
- Testing
- diet
- Where
- 2 sites in Iran
- Volunteers
- 48 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria
- Trial name
- NCT02503345
- Testing
- ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Allena Pharmaceuticals
Hyperoxaluria
Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk
The purpose of this study is to ascertain whether certain supplements promote excessive urinary oxalate excretion and increase the risk for calcium oxalate kidney stones.
- Trial name
- NCT02404701
- Testing
- Aloe vera with cactus, Cranberry, Green tea extract
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Hyperoxaluria (Disorder)
Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) Gene
Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure.
- Trial name
- HETEROX (NCT06283082)
- Testing
- Lithiasis assessment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT02547805
- Testing
- ALLN-177
- Where
- 22 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allena Pharmaceuticals